SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): July 15, 2003
-------------
CYTOGEN CORPORATION
-----------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-14879 222322400
---------------------------- ------------------------ -------------------
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)
650 College Road East, CN 5308, Suite 3100, Princeton, NJ 08540
--------------------------------------------------------- --------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (609) 750-8200
--------------
ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE.
On July 15, 2003, Advanced Magnetics, Inc. ("Advanced Magnetics")
and Cytogen Corporation ("Cytogen") announced, in a press release, the
presentation of data showing that magnetic resonance imaging (MRI) with
Combidex(R) (ferumoxtran-10), an investigational iron oxide nanoparticle, aids
in the non-invasive diagnosis of metastatic lymph nodes. The data was presented
by Dr. Mukesh Harisinghani, Assistant Radiologist at Massachusetts General
Hospital and Dr. Ralph Weissleder, Director of the Center for Molecular Imaging
Research at Massachusetts General Hospital, at the International Society for
Magnetic Resonance in Medicine (ISMRM) 11th Scientific Meeting held in Toronto,
July 10-16, 2003, and was from a study that included patients with breast and
prostate cancer. Cytogen has a license with Advanced Magnetics for exclusive
marketing rights to Combidex(R) in the United States.
Such press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference. The foregoing description of such press
release is qualified in its entirety by reference to such document.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
Exhibit No. Description
----------- ------------
99.1 Press release of the Company dated July 15, 2003.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this current report on Form 8-K to be signed on
its behalf by the undersigned hereunto duly authorized.
CYTOGEN CORPORATION
By: /s/ Michael D. Becker
-------------------------------------
Michael D. Becker
President and Chief Executive Officer
Dated: July 15, 2003
EXHIBIT INDEX
Exhibit No. Description
----------- -----------
99.1 Press release of the Company dated July 15, 2003.